Skip to content

Insider · CIK 0001944069

Richard A Colvin

officer

Files at BLUE (bluebird bio, Inc.). First filing Dec 12, 2024, latest Mar 5, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $4,116 sold

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
3Weak
BLUEsell 210b5-1
bluebird bio, Inc.
$2,289
584 shares
-7%-
3Weak
BLUEsell 210b5-1
bluebird bio, Inc.
$473
64 shares
-1%-
0Weak
BLUEsell10b5-1
bluebird bio, Inc.
$176
19 shares
-0%-
3Weak
BLUEsell 210b5-1
bluebird bio, Inc.
$1,178
2,824 shares
-2%-

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Dec 10, 2024 BLUE
bluebird bio, Inc.
2,824
0.00% of outstanding
$1,271Dec 10, 2024none

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 30, 2025BLUE
bluebird bio, Inc.
UTender of shares
Common Stock
-3,552--4,166Jun 3, 2025
Jun 2, 2025BLUE
bluebird bio, Inc.
DDisposition to issuer
Common Stock
-4,166--0Jun 3, 2025
Jun 2, 2025BLUE
bluebird bio, Inc.
AGrant or award
Common Stock
+2,500--2,500Jun 3, 2025
Jun 2, 2025BLUE
bluebird bio, Inc.
DDisposition to issuer
Common Stock
-2,500--0Jun 3, 2025
Mar 3, 2025BLUE
bluebird bio, Inc.
SOpen-market sale
Common Stock10b5-1
-584$3.92$2,2897,610Mar 5, 2025
Feb 3, 2025BLUE
bluebird bio, Inc.
SOpen-market sale
Common Stock10b5-1
-64$7.39$4738,194Feb 5, 2025
Jan 6, 2025BLUE
bluebird bio, Inc.
SOpen-market sale
Common Stock10b5-1
-19$9.24$1768,257Jan 8, 2025
Dec 10, 2024BLUE
bluebird bio, Inc.
SOpen-market sale
Common Stock10b5-1
-2,824$0.42$1,178165,544Dec 12, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard A Colvin: insider trades and track record | InsiderTell